Panorama Research Incorporated — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Novel Targeted Cytokine for Chronic Kidney Disease En
Panorama Research Incorporated — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,243
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): Novel Targeted Cytokine for Chronic Kidney Disease End stage renal disease (ESRD) affects gt485,000 Americans, including over 341,000 hemodialysis patients with an estimated 90,000 new cases per year. The annual cost oftreating Americans suffering from some form of kidney failure is about 23 billion. Progression of kidney disease is characterized by a persistent inflammatory response that causes irreversible renal glomerulosclerosis and tubulointerstitial fibrosis eventually leading to ESRD (reviewed in Kanamaru, 2008). Bone morphogenetic protein 7 (BMP7) plays an important role in kidney homeostasis through its interaction with activin-like-kinase receptors 2,3, 6 (alk2, alk3, alk6) an BMPR2. Treatment with or ectopicexpression of BMP7 in chronic kidney disease (CKD) blocks apoptosis, reduces inflammation, reverses the epithelial to mesenchymal transition (EMT) and fibrosis, inducing kidney regeneration [1] [2]. Recombinant BMP7 (rBMP7) would be a promising therape